Ensayo MORNINGLYTE: A Phase III randomized, open-label, international, multicenter study evaluating the efficacy and safety of mosunetuzumab plus lenalidomide in comparison to anti-CD20 mAb plus chemotherapy in subjects with previously untreated high-tumor burden follicular lymphoma. Grupo Lysa
|
Investigador Principal |
Dr. Armando López |
|
Estado del Protocolo |
Abierto en reclutamiento |
